Healthcare providers globally have faced unprecedented workloads since the outbreak of COVID-19 last year. The pandemic response has additionally altered how, where, and when care is provided, revealing the need for fundamental changes across care-related industries.   To address these and other challenges, Microsoft, which has long been at the forefront of the big-tech push into…

Despite rigorous border control and strict measures, COVID-19 has made its way into Taiwan. Now businesses, researchers, and government are working on innovations that will put Taiwan back in business. Until recently, Taiwan had a remarkable success record in containing the spread of COVID-19 and maintaining normality for its citizens. While hospitals worldwide had their…

Research-based biopharmaceutical multinational AstraZeneca, one of the earliest healthcare companies to enter the Taiwan market, has been working to deliver the best in patient care in Taiwan for over 70 years. The company’s dedication to advancing medical science is reflected in its innovation and outstanding performance in R&D. It is also focused on “beyond the…

Although a newcomer to the healthcare scene, global pharmaceutical company Viatris, formed in November 2020 through a merger of Upjohn, a legacy division of Pfizer, and Mylan, already has a sizable industry footprint. By combining the two complementary businesses, the merger has accelerated their ability to serve patients and expanded their resources across more than…

Last May, research-based global biopharmaceutical firm AbbVie finalized a transformative acquisition of Allergan, an Ireland-headquartered healthcare solutions provider. The transaction made AbbVie, a relatively young spinoff of the long-established Abbott Laboratories, the fifth largest biopharmaceutical company in the world. It further diversified the company’s robust product portfolio, expanded and strengthened its already robust R&D pipeline,…

The healthcare industry is currently undergoing a radical transformation. Patients increasingly have access to better, more personalized treatment options targeting previously intractable illnesses, allowing them to live longer, more fulfilling lives. Yet for Novartis, this hard work is just the beginning of the long journey. While the global healthcare ecosystem continues to flourish, reaching ever…